May 9, 2013
/PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of
per share, a two percent premium over the closing price on
May 8, 2013
, for gross proceeds of
. The shares were offered and are expected to be sold to RA Capital Management and other investors in a registered direct offering conducted without an underwriter or placement agent. The net proceeds from the offering, after deducting estimated offering expenses, will be approximately
. The offering is expected to close on or about
May 14, 2013
Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the potential commercialization of OMS302 for intraocular lens replacement, as well as for research and development expenses, such as funding planned clinical trials for its OMS103HP, PDE10, MASP-2 and PDE7 programs. The net proceeds may also be used to fund pre-clinical studies, capital expenditures, working capital and to otherwise advance Omeros' potential products towards commercialization.
The securities were offered by means of a prospectus supplement dated
May 9, 2013
and accompanying prospectus dated
October 18, 2010
, forming a part of the Company's effective shelf registration statement (File No. 333-169856). Omeros has filed a registration statement (including a prospectus) with the Securities and Exchange Commission, or SEC, for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents Omeros has filed with the SEC for more complete information about Omeros and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at
. Alternatively, Omeros will arrange to send you the prospectus if you request it by calling Omeros at 206-676-5000.